Avoiding Potential Pitfalls of Generic Substitution

Geriatric Nursing

Volumn 30, Issue 4, 2009, Pages 260-263

  Zarowitz, Barbara J ^a   Semla, Todd ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG;

ARTICLE; FOOD AND DRUG ADMINISTRATION; PHARMACOKINETICS; UNITED STATES;

ANTICONVULSANTS; DRUGS, GENERIC; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 68049143447     PISSN: 01974572     EISSN: 15283984     Source Type: Journal    
DOI: 10.1016/j.gerinurse.2009.06.002     Document Type: Article

References (15)

1. Zarowitz B.J. The generic imperative. Geriatr Nurs 29 (2008) 223-229
2. Kaiser Family Foundation. Prescription Drug Trends. 2008. Available at www.kff.org/rxdrugs/upload/3057_07.pdf. Cited May 16, 2009.
3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, "Generic Competition and Drug Prices." Available at www.fda.gov/cder/ogd/generic_competition.htm. Cited May 16, 2009.
4. Generic Pharmaceutical Association. www.gphaonline.org/Content/NavigationMenu/AboutGenerics/Statistics/default.htm.
5. Nightingale S. Therapeutic equivalence of generic drugs: letter to health practitioners. U.S. Food and Drug Administration, Center for Drug Effectiveness. 1998. Available at http://www.fda.gov/cder/news/nightgenlett.htm Cited May 16, 2009
6. Williams RL. Therapeutic equivalence of generic drugs: response to national associations of boards of pharmacy, 1997. Available at http://www.fda.gov/ohrms/dockets/dailys/03/Sept03/092403/03p-0315-c000001-08-tab-07-vol1.pdf. Cited July 8, 2009.
7. Approved Drug Products with Therapeutic Evaluations ("Orange Book"). U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 29th edition, February 2009. Available at www.fda.gov/cder/orange/obannual.pdf. Cited May 16, 2009.
8. Zachry III W.M., Doan Q.D., Clewell J.D., et al. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 50 (2009) 493-500
9. Berg M.J., Gross R.A., Tomaszewski K.J., et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71 (2008) 525-530
10. Andermann F., Sheng M., Gosselin A., et al. Compulsory generic switching of antiepileptic drugs; high switchback rates to branded compounds compared with other drug classes. Epilepsia 48 (2007) 464-469
11. Lelorier J., Duh M.S., Paradis P.E., et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 70 (2008) 2179-2186
12. Lelorier J., Duh M.S., Paradis P.E., et al. Substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Opin 24 (2008) 1069-1081
13. Duh M.S., Andermann F., Paradis P.E., et al. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting; the case of lamotrigine. Dis Manag 10 (2007) 216-225
14. Nielsen K.A., Dahl M., Tømmerup E., et al. Different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 13 (2008) 127-130
15. Vadney V.J., and Kraushaar K.W. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Ment Retard 35 (1997) 468-476